Up 80% in 6 months, this stock may still have 5% more upside

The company announced post market hours Thursday that it had settled a patent suit in the US for sale of a generic version cancer drug in that market. The short-term range for the stock is 4,546-5,054.

from Stocks-Markets-Economic Times https://ift.tt/3cbd8x0